CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/ BRAF Wild-Type mCRC Patients

Stefania Napolitano, Giulia Martini, Davide Ciardiello, Massimo Di Maio, Nicola Normanno, Antonio Avallone, Erika Martinelli, Evaristo Maiello, Teresa Troiani, Fortunato Ciardiello, Stefania Napolitano, Giulia Martini, Davide Ciardiello, Massimo Di Maio, Nicola Normanno, Antonio Avallone, Erika Martinelli, Evaristo Maiello, Teresa Troiani, Fortunato Ciardiello

Abstract

Introduction: Immunotherapy has limited efficacy in metastatic colorectal cancer (mCRC). Understanding mechanisms mediating immune resistance in microsatellite stable (MSS) colorectal tumors remains an ongoing challenge. Novel combination immunotherapy-based approaches have been developed under the rationale of overcoming immune resistance and developing effective immune response against colorectal tumor cells. Preclinical studies have demonstrated that cetuximab may modulate immune response to cancer cells. In this scenario, the inhibition of PD-L1 with IgG1 MAb avelumab in combination with anti-EGFR IgG1 monoclonal antibody cetuximab could be a strategy for potentiating antitumor activity. The CAVE phase II single-arm clinical trial provided the first evidence of clinical activity of combining cetuximab plus avelumab in 77 patients with RAS wild-type (WT) mCRC. This combination had a good toxicity profile, with a low rate of common grade 3 adverse events.

Patients and methods: Based on results obtained with the CAVE clinical trial, here we describe the design and rationale for the phase II, randomized CAVE 2 clinical study of the combination of avelumab plus cetuximab as a rechallenge strategy in pre-treated RAS, BRAF WT mCRC patients treated in first line with chemotherapy in combination with cetuximab and who have had a clinical benefit (complete or partial response) from treatment. A total of 173 patients will be randomized (2:1) to cetuximab + avelumab (115) or cetuximab as a single agent (58). The primary endpoint is overall survival. Key secondary endpoints include overall response rate, progression-free survival, and safety. For each patient, before treatment, a blood sample will be obtained and analyzed for circulating free tumor DNA according to NGS (Foundation/Roche), to identify RAS/BRAF WT patients to be enrolled. The same procedure will be performed at the progression of the disease. Additional blood/plasma, tumor, and fecal samples will be collected and centrally stored for additional translational studies.

Discussion: This study will provide the rationale to test immunotherapy-based combinations in the clinical setting, offering new opportunities for RAS WT mCRC patients.

Clinical trial registration: [https://ichgcp.net/clinical-trials-registry/NCT05291156], identifier [NCT05291156].

Keywords: avelumab; cetuximab; mCRC; phase II trial; rechallenge.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Napolitano, Martini, Ciardiello, Di Maio, Normanno, Avallone, Martinelli, Maiello, Troiani and Ciardiello.

Figures

Figure 1
Figure 1
CAVE-2 study design.
Figure 2
Figure 2
Criteria for withdrawal from trial treatment.
Figure 3
Figure 3
Inclusion and exclusion criteria.

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71:209–49. doi: 10.3322/caac.21660
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics. CA Cancer J Clin (2022) 72:7–33. doi: 10.3322/caac.21708
    1. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. . ESMO Consensus Guidelines for the Management of Patients With Metastatic Colorectal Cancer. Ann Oncol (2016) 27:1386–422. doi: 10.1093/annonc/mdw235
    1. Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical Management of Metastatic Colorectal Cancer in the Era of Precision Medicine. CA Cancer J Clin (2022) 0:1–30. doi: 10.3322/caac.21728
    1. De Falco V, Napolitano S, Roselló S, Huerta M, Cervantes A, Ciardiello F, et al. . How We Treat Metastatic Colorectal Cancer. ESMO Open (2020) 4(Suppl 2):e000813. doi: 10.1136/esmoopen-2020-000813
    1. Troiani T, Napolitano S, Della Corte CM, Martini G, Martinelli E, Morgillo F, et al. . Therapeutic Value of EGFR Inhibition in CRC and NSCLC: 15 Years of Clinical Evidence. ESMO Open (2016) . 1:e000088. doi: 10.1136/esmoopen-2016-000088
    1. Martini G, Ciardiello D, Vitiello PP, Napolitano S, Cardone C, Cuomo A, et al. . Resistance to Anti-Epidermal Growth Factor Receptor in Metastatic Colorectal Cancer: What Does Still Need to be Addressed? Cancer Treat Rev (2020) 86:102023. doi: 10.1016/j.ctrv.2020.102023
    1. Parseghian CM, Napolitano S, Loree JM, Kopetz S. Mechanisms of Innate and Acquired Resistance to Anti-EGFR theraPy: A Review of Current Knowledge With a Focus on a Rechallenge Therapies. Clin Cancer Res (2019) 25:6899–08. doi: 10.1158/1078-0432.CCR-19-0823
    1. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, et al. . Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-Challenge. Ann Oncol (2018) 30:243–9. doi: 10.1093/annonc/mdy509
    1. Ciardiello F, Normanno N, Martinelli E, Troiani T, Pisconti S, Cardone C, et al. . Cetuximab Continuation After First Progression in Metastatic Colorectal Cancer (CAPRI-GOIM): A Randomized Phase II Trial of FOLFOX Plus Cetuximab Versus FOLFOX. Ann Oncol (2016) 27:1055–61. doi: 10.1093/annonc/mdw136
    1. Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, et al. . Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-Line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. JAMA Oncol (2019) 5:343–50. doi: 10.1001/jamaoncol.2018.5080
    1. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. . KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med (2020) 383:2207–18. doi: 10.1056/NEJMoa2017699
    1. Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, et al. . Prospects for Combining Targeted and Conventional Cancer Therapy With Immunotherapy. Nat Rev Cancer (2017) 17:286–301. doi: 10.1038/nrc.2017.17
    1. Inoue Y, Hazama S, Suzuki N, Tokumitsu Y, Kanekiyo S, Tomochika S, et al. . Cetuximab Strongly Enhances Immune Cell Infiltration Into Liver Metastatic Sites in Colorectal Cancer. Cancer Sci (2017) 108:455–60. doi: 10.1111/cas.13162
    1. Fasano M, Della Corte CM, Di Liello R, Barra G, Sparano F, Viscardi G, et al. . Induction of Natural Killer Antibody-Dependent Cell Cytotoxicity and of Clinical Activity of Cetuximab Plus Avelumab in non-Small Cell Lung Cancer. Esmo Open (2020) 5:e000753. doi: 10.1136/esmoopen-2020-000753
    1. Martinelli E, Martini G, Famiglietti V, Troiani T, Napolitano S, Pietrantonio F, et al. . Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. JAMA Oncol (2021) 7:1529–35. doi: 10.1001/jamaoncol.2021.2915
    1. Tao Y, Aupérin A, Sun X, Sire C, Martin L, Coutte A, et al. . Avelumab-Cetuximab-Radiotherapy Versus Standards of Care in Locally Advanced Squamous-Cell Carcinoma of the Head and Neck: The Safety Phase of a Randomised Phase III Trial GORTEC 2017-01 (REACH). Eur J Cancer (2020) 141:21–9. doi: 10.1016/j.ejca.2020.09.008
    1. Stein A, Binder M, Goekkurt E, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, et al. . Avelumab and Cetuximab in Combination With Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (mCRC): Final Results of the Phase Ii Avetux Trial (Aio-Krk-0216). J Clin Oncol (2020) 38(4_suppl):96. doi: 10.1200/JCO.2020.38.4_suppl.96
    1. Den Eynde MV, Huyghe N, De Cuyper A, Sinapi I, Ferrier M, Gilet M, et al. . Interim Analysis of the AVETUXIRI Trial: Avelumab Combined With Cetuximab and Irinotecan for Treatment of Refractory Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)—A Proof of Concept, Open-Label, Nonrandomized Phase IIa Study. J Clin Oncol (2021) 39:80–0. doi: 10.1200/JCO.2021.39.3_suppl.80
    1. Caputo V, De Falco V, Ventriglia A, Famiglietti V, Martinelli E, Morgillo F, et al. . Comprehensive Genome Profiling by Next Generation Sequencing of Circulating Tumor DNA in Cancer: A Single Academic Institution Prospective Evaluation. Ther Adv Med Oncol (2022) 14:1–15. doi: 10.1177/17588359221096878

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅